What Biogen's Quarter ended Sep 30, 2026 10-Q says: 4 signals
Biogen filed its latest 10-Q with the SEC on Oct 28, 2026. It discusses acquisition completed, compliance burden and debt refinancing.
Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn
Get Biogen's live signals in Claude or ChatGPT, or by API
What changed at Biogen this week? Use Autobound signals for biogen.com.- Filed
- Oct 28, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 12
Source: Autobound Signal API · 74 signals tracked for Biogen · updated
10-Q · latest 10
What Biogen's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
Completed $225M acquisition of RayThera Inc. on August 6, 2026
Biogen completed the acquisition of private biotechnology firm RayThera Inc.
$225M
upfront cash payment for the acquisition of RayThera Inc.
Biogen Secures $2.4B Debt Financing via Term Loan and Credit Facility Drawdown
Biogen funded its acquisition of Apellis in part through the issuance of a $2.0 billion term loan under its 2026 Term Loan and a $400.0 million drawdown from its revolving credit facility.
U.S. Administration Imposes 100% Tariffs on Patented Pharmaceuticals and Biologics
Following a Section 232 investigation, the U.S.
100%
tariff on imports of patented pharmaceuticals, biologics and associated ingredients
Biogen Relies on Single Chinese Supplier for Key SKYCLARYS Starting Materials
Biogen disclosed that certain starting materials for SKYCLARYS rely on a single supplier based in China, although downstream drug substance processing is primarily conducted in the U.S.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
Completed acquisition of Apellis Pharmaceuticals on May 14, 2026, for approximately $5.3 billion
Biogen completed the acquisition of Apellis on May 14, 2026, for $41.00 per share in cash totaling approximately $5.3 billion, adding SYFOVRE and EMPAVELI.
$5.3B
cash consideration for acquisition of Apellis
Entered definitive agreement to acquire RayThera Inc. in June 2026
Biogen entered into a definitive agreement in June 2026 to acquire all issued and outstanding shares of RayThera Inc.
Biogen Raised $2.0B Term Loan and Drew $400.0M Credit Facility for Apellis Acquisition
Biogen funded the Apellis acquisition using cash on hand supplemented by a $2.0 billion term loan under its 2026 Term Loan and a $400.0 million drawdown from its revolving credit facility.
U.S. Administration Imposes 100% Tariff on Patented Pharmaceuticals and Biologics Under Section 232
Following a national security investigation under Section 232, the U.S.
100%
tariff on imports of patented pharmaceuticals, biologics and associated ingredients
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 4 signals
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in March 2026
Biogen entered into an agreement to acquire Apellis Pharmaceuticals for $41.00 per share in cash plus contingent value rights, funded via $3.6 billion of cash and $2.0 billion in bank loans.
$5.6B
expected total transaction value to acquire Apellis Pharmaceuticals
IRA Medicare Part D redesign creates $90.0 million unfavorable net impact on 2025 revenue
The IRA's drug pricing controls and Medicare Part D redesign had an adverse impact on sales, creating a net unfavorable impact of approximately $90.0 million to full-year 2025 revenue, concentrated in SKYCLARYS and MS products.
$90M
unfavorable impact to full-year 2025 revenue from IRA Medicare Part D redesign
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Biogen earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| LEQEMBI iClick outpacing Kisunla launch uptake by sixfoldBiogen reported that early commercial launch uptake for LEQEMBI iClick is outpacing IV administration by 3.5x and rival Alzheimer's therapy Kisunla by 6x. The subcutaneous formulation is attracting new prescribers who had never previously written an anti-amyloid therapy. | |
| Targeting $250M run rate synergies from Apellis integrationBiogen has accelerated cost synergy identification following its Apellis acquisition, remaining on track to realize $250 million in run-rate synergies by the end of 2027. Operating dilution in 2026 is already negligible, with the transaction expected to be accretive to non-GAAP diluted EPS in 2027. | |
| Part D formulary restrictions reduce VUMERITY revenue 11%VUMERITY revenue fell 11% year over year to $192 million due to tighter formulary management by payers under Medicare Part D post-IRA. Biogen anticipates these macro reimbursement pressures to persist across Part D drugs through the remainder of the year. | |
| Rebuilding early research pipeline targeting 20 clinical programsBiogen completed an overhaul of its research and early development organization, delivering 5 INDs in a single year after a three-year drought. Top leadership aims to scale the early-stage portfolio to at least 20 active programs over the next few years. | |
| Advancing clinical pipeline partnership with Stoke in DravetBiogen is actively partnering with Stoke Therapeutics to report registrational Phase 3 clinical data for zorubunursen in Dravet syndrome, expected in Q3 2027. The company is evaluating an addressable market opportunity of at least $1 billion outside the US. | |
| Deploying predictive AI tools to identify rare disease patientsBiogen has implemented AI predictive models and commercial patient-finding tools to locate rare disease patients for SKYCLARYS. The company attributes improved conversion and efficiency to these digital tools across field operations. |
Signal API · MCP
Track Biogen with the Signal API
One POST /v1/companies/enrich call with biogen.com returns Biogen 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Biogen 10-Q
When did Biogen file its latest 10-Q?
What did Biogen disclose in its latest 10-Q?
What did Biogen say on its recent earnings calls?
Where can I read Biogen's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .